Tuesday, 5 April 2016

FDA: Zika – blood and blood products

Global health concerns regarding the Zika virus, a flavivirus, have prompted the U.S. FDA to issue guidance for blood donation collection, recommending that donors at risk for the virus defer donations for four weeks. The FDA also noted in its guidance that it is unlikely for the virus to be transmitted through fractionated plasma-derived products, such as intravenous immunoglobulin (IVIG) or von Willebrand factor (VWF) and coagulation factor VIII (FVIII) because of existing viral inactivation and removal methods.

For further details, see FDA.

 Posted by Dr. Tim Sandle

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers